New dual therapy targets Hard-to-Treat gut cancers
NCT ID NCT07544589
First seen Apr 26, 2026 · Last updated May 02, 2026 · Updated 3 times
Summary
This early-stage study tests a new treatment called DISP-10 for people with advanced cancers of the stomach, esophagus, or colon that have spread. DISP-10 combines a virus that attacks cancer cells with a special immune cell therapy (CAR T-cells) that targets a protein on those cells. The goal is to find a safe dose and see if the treatment can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
-
Tennessee Oncology
RECRUITINGNashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.